- Home
- PMX vs FULC Comparison
PMX vs FULC Comparison
Compare PMX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMX
- FULC
- Stock Information
- Founded
- PMX 2002
- FULC 2015
- Country
- PMX United States
- FULC United States
- Employees
- PMX N/A
- FULC N/A
- Industry
- PMX Trusts Except Educational Religious and Charitable
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- PMX Finance
- FULC Health Care
- Exchange
- PMX Nasdaq
- FULC Nasdaq
- Market Cap
- PMX 269.1M
- FULC 221.5M
- IPO Year
- PMX N/A
- FULC 2019
- Fundamental
- Price
- PMX $7.85
- FULC $3.01
- Analyst Decision
- PMX
- FULC Hold
- Analyst Count
- PMX 0
- FULC 10
- Target Price
- PMX N/A
- FULC $7.44
- AVG Volume (30 Days)
- PMX 101.5K
- FULC 727.6K
- Earning Date
- PMX 01-01-0001
- FULC 11-13-2024
- Dividend Yield
- PMX 5.28%
- FULC N/A
- EPS Growth
- PMX N/A
- FULC N/A
- EPS
- PMX N/A
- FULC N/A
- Revenue
- PMX N/A
- FULC $80,871,000.00
- Revenue This Year
- PMX N/A
- FULC $2,821.96
- Revenue Next Year
- PMX N/A
- FULC N/A
- P/E Ratio
- PMX N/A
- FULC N/A
- Revenue Growth
- PMX N/A
- FULC 2987.86
- 52 Week Low
- PMX $6.09
- FULC $2.87
- 52 Week High
- PMX $8.47
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- PMX 43.05
- FULC 32.66
- Support Level
- PMX $7.81
- FULC $3.38
- Resistance Level
- PMX $8.10
- FULC $3.94
- Average True Range (ATR)
- PMX 0.11
- FULC 0.21
- MACD
- PMX 0.00
- FULC 0.05
- Stochastic Oscillator
- PMX 22.73
- FULC 5.55
About PMX PIMCO Municipal Income Fund III of Beneficial Interest
PIMCO Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as transportation, healthcare, and others.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.